Related references
Note: Only part of the references are listed.CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept
Geeta Karadkhele et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial
E. Steve Woodle et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Opportunistic infections after conversion to belatacept in kidney transplantation
Dominique Bertrand et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Avoidance of CNI and steroids using belatacept-Results of the Clinical Trials in Organ Transplantation 16 trial
Roslyn B. Mannon et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol
Paolo Malvezzi et al.
TRANSPLANT IMMUNOLOGY (2019)
De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies
R. A. Bray et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study
Amandine Darres et al.
TRANSPLANTATION (2018)
Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study
D. Bertrand et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function
A. B. Adams et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors
Y. Le Meur et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Belatacept and Long-Term Outcomes in Kidney Transplantation
Flavio Vincenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Summary of the US FDA Approval of Belatacept
P. Archdeacon et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Immunosuppression with Belatacept-Based, Corticosteroid-Avoiding Regimens in De Novo Kidney Transplant Recipients
R. Ferguson et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)
A. Durrbach et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
F. Vincenti et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies
Christian P. Larsen et al.
TRANSPLANTATION (2010)
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties
CP Larsen et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Share Paper
